Publications

Filters

ADJournallogo_sm

Dissecting Alzheimer's proteomic landscape through NULISA profiling of brain cell-specific extracellular vesicles

ERS 500 x 500 px

Clinical parameters and blood biomarkers associated with response to mepolizumab in severe asthma

GeroScience 500 x 500 px

Lifestyle and psychosocial protective factors drive healthy aging and modulate inflammatory and metabolic pathways

Annals of Clinical and Translational Neurology 500 x 500 px

Evaluation of Dried Plasma Spot-Based Quantification of Glial Fibrillary Acidic Protein as a Disease-Associated Biomarker in Neuromyelitis Optica Spectrum Disorder

EJNMMI 500 px
JTCVS 500 px

Proteomic, transcriptomic, and metabolic mediators of postcardiopulmonary bypass vasoplegia syndrome

NNN 500 px
European Journal of Neurology 500

Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia

ADJournallogo_sm

Identifying populations with faster cognitive decline using blood-based biomarkers

Neurobiology of Aging 500

Associations among cognitive performance, VCAM-1, and GFAP in black adults: The ARCHES study

MedRxiv_homepage_logo
biorxiv_article

Dissociable structural and molecular pathways of age-related change in sustained attention

0 - 0 of 0 documents
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.